MLTX INVESTOR NOTICE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP is pursuing a class action lawsuit against MoonLake Immunotherapeutics (MLTX) for alleged misleading statements.Summary
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who purchased the company’s stock. The lawsuit alleges that MoonLake made false and misleading statements regarding its drug candidate, sonelokimab (“SLK”), and its potential to compete with Union Chimique Belge's BIMZELX. Specifically, the complaint claims that SLK’s Nanobody structure would not provide a clinical benefit over BIMZELX, and its tissue penetration would not translate to efficacy. Following the announcement of Phase 3 trial results on September 28, 2025, which showed SLK failed to demonstrate competitive efficacy, MoonLake’s stock price fell nearly 90%. Investors who suffered substantial losses are encouraged to seek the role of lead plaintiff by contacting Robbins Geller by December 15, 2025, to potentially recover losses through legal action.
(Source：GuruFocus)